Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
| Status: | Terminated |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2010 |
| End Date: | August 2012 |
Positron Emission Mammography (PEM) is a newly developed imaging examination of the breast
that uses a radioactive glucose based tracer, which is a form of sugar attached to a low
radiation agent, to detect cancer cells. The radioactive glucose based tracer is called
fluorodeoxyglucose (FDG), and it is FDA approved. A PEM scanner is able to better detect
cancer cells within the breast, more than a regular PET scanner. The PEM scanner is also FDA
approved. This type of imaging may be able to see the breast cancer before it could be seen
with mammograms and may be as good as or better than breast MRI.
The purpose of this study is to compare the value of FDG Positron Emission Mammography (PEM)
with contrast enhanced Magnetic Resonance Imaging (MRI) of the breast for patients with
breast cancer. This study will also perform special pathology test to compare the FDG PEM
and contrast enhanced breast MRI images with the results from the standard of care breast
surgery. This may teach us more about the biology of each breast tumor.
that uses a radioactive glucose based tracer, which is a form of sugar attached to a low
radiation agent, to detect cancer cells. The radioactive glucose based tracer is called
fluorodeoxyglucose (FDG), and it is FDA approved. A PEM scanner is able to better detect
cancer cells within the breast, more than a regular PET scanner. The PEM scanner is also FDA
approved. This type of imaging may be able to see the breast cancer before it could be seen
with mammograms and may be as good as or better than breast MRI.
The purpose of this study is to compare the value of FDG Positron Emission Mammography (PEM)
with contrast enhanced Magnetic Resonance Imaging (MRI) of the breast for patients with
breast cancer. This study will also perform special pathology test to compare the FDG PEM
and contrast enhanced breast MRI images with the results from the standard of care breast
surgery. This may teach us more about the biology of each breast tumor.
Inclusion Criteria:
- Female patients with recently diagnosed invasive or in situ breast cancer by core
needle biopsy or FNA (confirmed at MSKCC) prior to enrollment.
- Patients planning treatment with mastectomy at MSKCC.
- Patients 21 years old or older.
- Patients who had or are having a breast MRI within 30 days or less of PEM.
- Patients who had or are having a digital mammogram.
Exclusion Criteria:
- Patients who are pregnant or breast feeding.
- Patients with prior radiation therapy or endocrine therapy.
- Patients who had a prior lumpectomy.
- Patients who are diabetic.
- Patients with moderate to end stage kidney disease.
- Patients who have a contraindication to MRI (i.e. pacemaker, metallic implants, etc).
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
